Palvella Therapeutics, Inc. Cash and Cash Equivalents
Palvella Therapeutics, Inc. (PVLA) had Cash and Cash Equivalents of $187.80 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-04
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $187.80M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $206.39M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $57.98M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $63.57M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $187.80M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $206.39M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $57.98M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $63.57M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $70.43M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $75.63M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $83.60M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $19.36M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $19.73M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $19.08M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $7.35M 10-K · filed 2025-03-31 | $17.40M 10-K · filed 2024-03-29 |
| 2023-09-30 | $32.89M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $44.94M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $39.74M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $38.63M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $48.42M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $54.26M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $83.74M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $117.76M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $125.05M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $119.10M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $66.83M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $70.44M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $66.89M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $44.30M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $47.43M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $62.26M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $46.07M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $54.90M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $52.09M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $74.87M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $89.48M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $50.58M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $109.52M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $37.88M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $89.92M 10-Q · filed 2018-11-07 | $89.92M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $50.32M 10-Q · filed 2018-08-09 | $50.33M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $55.24M 10-Q · filed 2018-05-10 | $55.24M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $29.36M 10-K · filed 2019-03-18 | $29.36M 10-K · filed 2017-03-30 |
| 2016-09-30 | $36.56M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | $40.37M 10-Q · filed 2017-08-11 | |
| 2016-03-31 | $31.19M 10-Q · filed 2017-05-15 | |
| 2015-12-31 | $29.35M 10-K · filed 2018-03-15 | $29.35M 10-K · filed 2016-03-23 |
| 2015-09-30 | $32.25M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $10.03M 10-Q · filed 2016-08-11 | |
| 2015-03-31 | $13.17M 10-Q · filed 2016-05-12 | |
| 2014-12-31 | $18.47M 10-K · filed 2017-03-30 | |
| 2014-09-30 | $936.18K 10-Q · filed 2015-11-13 | $220.00 10-Q · filed 2014-11-13 |
| 2014-06-30 | $1.49M 10-Q · filed 2015-08-13 | $11.14K 10-K · filed 2014-09-12 |
| 2014-03-31 | $3.27M 10-Q · filed 2015-05-14 | $196.00 10-Q · filed 2014-06-02 |
| 2013-12-31 | $3.69M 10-K · filed 2016-03-23 | $90.00 10-Q · filed 2014-05-14 |
| 2013-09-30 | $688.00 10-Q · filed 2014-12-12 | |
| 2013-06-30 | $5.20K 10-Q · filed 2014-12-12 | |
| 2013-05-23 | $0.00 10-Q · filed 2014-11-13 | |
| 2012-12-31 | $6.33M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |